Alliance Pharma PLC Share Options (7944N)
October 28 2016 - 12:13PM
UK Regulatory
TIDMAPH
RNS Number : 7944N
Alliance Pharma PLC
28 October 2016
28 October 2016
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Share Options
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical
company, announces that on 27(th) October 2016 it awarded the
following options over ordinary shares of the Company to certain
Directors.
Name Position Number Exercise Date of Percentage
of Share price vesting of issued
Options per Share ordinary
Awarded share
capital
-------------- ------------ ---------- ----------- --------- -----------
Chief
Andrew Financial October
Franklin Officer 155,000 47.50 2018 0.033
-------------- ------------ ---------- ----------- --------- -----------
Chief
Andrew Financial October
Franklin Officer 400,000 47.50 2020 0.085
-------------- ------------ ---------- ----------- --------- -----------
Deputy
Chief
Peter Executive October
Butterfield Officer 200,000 47.50 2018 0.042
-------------- ------------ ---------- ----------- --------- -----------
Deputy
Chief
Peter Executive October
Butterfield Officer 1,000,000 47.50 2020 0.212
-------------- ------------ ---------- ----------- --------- -----------
The vesting of the awards that are scheduled to vest in October
2018 is subject to continued employment and the vesting of the
awards that are scheduled to vest in October 2020 is subject to
continued employment and the satisfaction of certain performance
conditions.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Andrew Franklin, Chief Financial
Officer
Sarah Robinson, Company Secretary
www.alliancepharma.co.uk
+ 44 (0) 20 7466
Buchanan 5000
Mark Court / Sophie Cowles
/ Jane Glover
+ 44 (0) 20 7260
Numis Securities Limited 1000
Nominated Adviser: Michael
Meade / Freddie Barnfield
Corporate Broking: James
Black / Toby Adcock
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international specialty
pharmaceutical company based in Chippenham, Wiltshire, UK. The
Company has sales in more than 100 countries worldwide via direct
sales, joint ventures and a network of distributors. Alliance has a
strong track record of acquiring the rights to established niche
products and it currently owns or licenses the rights to
approximately 90 pharmaceutical and consumer healthcare products.
The Company continues to explore opportunities to expand its
product portfolio.
Alliance joined the AIM market of the London Stock Exchange in
December 2003 and trades under the symbol APH.
1 Details of the person discharging managerial
responsibilities / person closely associated
--- --------------------------------------------------------------------------
a) Name 1. Andrew Franklin 2. Peter
Butterfield
--- ------------------------- -----------------------------------------------
2 Reason for the notification
--- --------------------------------------------------------------------------
a) Position/status 1. Chief Financial Officer
2. Deputy Chief Executive
Officer
--- ------------------------- -----------------------------------------------
b) Initial notification Initial
/Amendment
--- ------------------------- -----------------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- --------------------------------------------------------------------------
a) Name Alliance Pharma plc
--- ------------------------- -----------------------------------------------
b) LEI n/a
--- ------------------------- -----------------------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- --------------------------------------------------------------------------
a) Description of Options to subscribe for
the financial new ordinary shares of 1p
instrument, type each
of instrument
ISIN: GB0031030819
Identification
code
--- ------------------------- -----------------------------------------------
b) Nature of the Grant of options
transaction
--- ------------------------- -----------------------------------------------
c) Price(s) and volume(s) Exercise Price(s) Volume(s)
------------------ -------------------------
1. 47.5p per 1. 555,000
share 2. 47.5p 2. 1,200,000
per share
------------------ -------------------------
--- ------------------------- -----------------------------------------------
d) Aggregated information Total 1,755,000 options granted
at a price of 47.5p per share
- Aggregated volume
- Price
--- ------------------------- -----------------------------------------------
e) Date of the transaction 27 October 2016
--- ------------------------- -----------------------------------------------
f) Place of the transaction Outside of trading venue
--- ------------------------- -----------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHAKFDKABDDCKB
(END) Dow Jones Newswires
October 28, 2016 12:13 ET (16:13 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Feb 2024 to Mar 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2023 to Mar 2024